title: Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?
authors.forename: M
authors.initials: M
authors.lastname: Breccia
authors.forename: L
authors.initials: L
authors.lastname: Cannella
authors.forename: C
authors.initials: C
authors.lastname: Stefanizzi
authors.forename: A
authors.initials: A
authors.lastname: Carotti
authors.forename: M
authors.initials: M
authors.lastname: Santopietro
authors.forename: G
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D000069439:Dasatinib; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib